Insider Cluster (2 insiders) ·Filed Jun 11, 2026

NUVL

Nuvalent, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago
Insider cluster: 2 insiders, $3.6M total
Actionable Insight • Neutral

The insider cluster is trivial and should not influence trading decisions. Focus on the GSK acquisition: monitor regulatory approval and tender process for Q3 2026 close. The $124/share offer represents a premium to recent trading levels.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
NUVL ▲ +0.53% at T+20d
NEUTRAL call ✓ call won +0.53% · α vs SPY -1.25% · entry $123.25 → $123.90
Next anchor: T+60d due 24d ago
Latest observation: T+26 -6.45% FF3 residual α
Entry anchored
Jun 11, 03:59 PM ET
via exchange tick
T+1d
+0.08%
call +0.08% · α -1.68%
$123.35
settled 4mo ago
T+5d
+0.15%
call +0.15% · α -0.53%
$123.43
settled 4mo ago
T+20d
+0.53%
call +0.53% · α -1.25%
$123.90
settled 3mo ago
T+60d
—
call — · α —
—
due 24d ago

Price Chart

Loading chart...

Executive Summary

Two Nuvalent insiders (CEO and Chief Development Officer) sold a combined ~$3.56M in open-market shares on June 8-9, 2026, alongside derivative exercises. The sales represent only ~0.04% of market cap and are routine option-exercise-related transactions. The dominant event is GSK's $10.6B acquisition of Nuvalent at $124/share, announced June 9, rendering these insider sales immaterial.

Key Financial Metrics

Direction
selling
Total Value
$3.6M
Insiders
2

Key Facts

  • CEO James Porter exercised 60,000 options (30k at $18.93, 30k at $0) and sold 12,495 shares for ~$1.10M on June 8.
  • CDO Darlene Noci exercised 20,000 options (10k at $0, 10k at $1.08) and sold 20,000 shares for ~$2.46M on June 9.
  • Total open-market sales: ~$3.56M, or 0.037% of Nuvalent's $9.7B market cap.
  • GSK announced acquisition of Nuvalent for $124/share in cash on June 9, 2026, valuing equity at $10.6B.
  • Insider sales occurred after the deal announcement and are consistent with routine option cash-outs, not informed selling.

Financial Impact

Insider sales of ~$3.56M are negligible relative to the $10.6B acquisition value and $9.7B market cap.

dilutioninsider ownership

Risk Factors

  • Regulatory or antitrust hurdles delaying or blocking the GSK acquisition.
  • Shareholder approval or minimum tender condition not met.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (24 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NUVL-1781209982276
18 reports for NUVL
Performance horizon
38% Hit rate 3 of 8 directional calls best @ T+60▲ +21.01%Apr 7, 2026
Filters
Rows
Reports for NUVL — sortable, filterable
TypeNow
Jul 27, 2026
9w ago
15-12G
NEUTRAL ★ 3/10
—awaiting T+5——
Jul 15, 2026
11w ago
25-NSE
NEUTRAL ★ 3/10
$123.96 $123.96· 0.00%▲ +0.98%—
Jul 15, 2026
11w ago
8-K
BULLISH ★ 5/10
$123.96 $123.96· 0.00%▲ +0.98%—
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.80 $123.96▲ +0.13%▼ −0.73%—
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.72 $123.90▲ +0.15%▼ −0.34%—
Jun 11, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$123.25 $123.43▲ +0.15%▼ −0.53%—
Jun 10, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.45 $123.36▼ −0.07%▼ −0.51%—
Jun 9, 2026
16w ago
8-K
BULLISH ★ 8/10
$123.25 $123.35▲ +0.08%▼ −2.33%—
May 7, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$102.40 $105.22▲ +2.75%▲ +1.25%—
Apr 29, 2026
22w ago
Insider Cluster
NEUTRAL ★ 2/10
$99.10 $101.47▲ +2.39%▼ −0.72%—
Showing 10 of 18

US Market Status

Market Open — Closes in 3h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 11, 2026